Ultragenyx Pharmaceutical Aktie - 0LIF

Rendering Error

Professionelle Tools für Privatanleger.

Premium

Current Price

64,79

Gebot

0,00

Fragen

0,00

Volumen

148

0,00 Tagesbereich 0,00

64,79 52-Wochen-Bereich 64,79

Marktkapitalisierung

5,983B

Handelsende

64,79

Handelsbeginn

Letzte Trade

38.93

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

332

Ausgegebene Aktien

92.344.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-6,36

Gewinn pro Aktie (EPS)

-6,16

Erlöse

560,23M

Nettogewinn

-569,18M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.ultragenyx.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Ultragenyx Pharmaceutical Inc is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0LIF. The last closing price for Ultragenyx Pharmaceutical was US$64,79. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of US$ 64,79 to US$ 64,79.

Ultragenyx Pharmaceutical currently has 92.344.000 shares in issue. The market capitalisation of Ultragenyx Pharmaceutical is US$5,98 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -6.36.

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial...

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial...

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia...

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and...

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with...

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare...

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein Evkeeza®...

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	64.79	64.79	64.79	90	64.79	DE
4	64.79	64.79	64.79	200	64.79	DE
12	64.79	64.79	64.79	332	64.79	DE
26	64.79	64.79	64.79	452	64.79	DE
52	64.79	64.79	64.79	360	64.79	DE
156	64.79	64.79	64.79	531	64.79	DE
260	64.79	64.79	64.79	333	64.79	DE

0LIF - Frequently Asked Questions (FAQ)

What is the current Ultragenyx Pharmaceutical share price?

The current share price of Ultragenyx Pharmaceutical is US$ 64,79

How many Ultragenyx Pharmaceutical shares are in issue?

Ultragenyx Pharmaceutical has 92.344.000 shares in issue

What is the market cap of Ultragenyx Pharmaceutical?

The market capitalisation of Ultragenyx Pharmaceutical is USD 5,98B

What is the 1 year trading range for Ultragenyx Pharmaceutical share price?

Ultragenyx Pharmaceutical has traded in the range of US$ 64,79 to US$ 64,79 during the past year

What is the PE ratio of Ultragenyx Pharmaceutical?

The price to earnings ratio of Ultragenyx Pharmaceutical is -6,36

What is the cash to sales ratio of Ultragenyx Pharmaceutical?

The cash to sales ratio of Ultragenyx Pharmaceutical is 6,46

What is the reporting currency for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical reports financial results in USD

What is the latest annual turnover for Ultragenyx Pharmaceutical?

The latest annual turnover of Ultragenyx Pharmaceutical is USD 560,23M

What is the latest annual profit for Ultragenyx Pharmaceutical?

The latest annual profit of Ultragenyx Pharmaceutical is USD -569,18M

What is the registered address of Ultragenyx Pharmaceutical?

The registered address for Ultragenyx Pharmaceutical is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the Ultragenyx Pharmaceutical website address?

The website address for Ultragenyx Pharmaceutical is www.ultragenyx.com

Which industry sector does Ultragenyx Pharmaceutical operate in?

Ultragenyx Pharmaceutical operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
CSCChesterfield Special Cylinders Holdings Plc	35,00p (366,67%)	30k
GCMGcm Resources Plc	3,90p (39,29%)	11,89M
CLONClontarf Energy Plc	0,0345p (25,45%)	285,33M
ASCAsos Plc	309,60p (21,41%)	2,01M
TLYTotally Plc	3,75p (20,00%)	6,73M
ORNTOrient Telecoms Plc	4,00p (-50,00%)	7,5k
FPPFragrant Prosperity Holdings Limited	0,325p (-31,58%)	2,15M
ASHIAshington Innovation Plc	0,65p (-23,53%)	75k
BIGBig Technologies Plc	64,60p (-19,25%)	16,16M
MDZMediazest Plc	0,0675p (-15,63%)	4M
TRPTower Resources Plc	0,029p (-1,69%)	1,17B
PREMPremier African Minerals Limited	0,01165p (2,19%)	710,22M
VELAVela Technologies Plc	0,003p (-3,23%)	528,67M
MSMNMosman Oil And Gas Limited	0,0255p (-3,77%)	366,82M
EMEEmpyrean Energy Plc	0,10p (2,56%)	309,78M

Rendering Error

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Ultragenyx Pharmaceutical Inc (0LIF)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Ultragenyx Pharmaceutical Inc

0LIF Neueste Nachrichten

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

0LIF - Frequently Asked Questions (FAQ)

Beweger

0LIF Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Ultragenyx Pharmaceutical Inc (0LIF) Börsenkurse

Ultragenyx Pharmaceutical Inc (0LIF)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Ultragenyx Pharmaceutical Inc

0LIF Neueste Nachrichten

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

0LIF - Frequently Asked Questions (FAQ)

Beweger

0LIF Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen